Biosimilar Enbrel filed with EMA
This article was originally published in Scrip
The next biosimilar to reach the EU market could well be a version of Amgen's TNF inhibitor Enbrel, after the European Medicines Agency revealed in a January update that its scientific committee, the CHMP, has a biosimilar etanercept under evaluation.
You may also be interested in...
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.
The new EU commissioner for health has been given a number of high-priority tasks, including medicines supply and tackling antimicrobial resistance. These topics will be taken up by the European Commission’s advisory body, the Pharmaceutical Committee, in its new work plan.
Two EU bodies want to move forward with European Commission proposals on contamination of the environment by pharmaceutical substances.